Selleck Chemicals - Model A2760 -Lintuzumab (Anti-Siglec-3 / CD33)

Lintuzumab (HuM195) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. MW: 145. 24 kD.